Literature DB >> 8580783

Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia.

P Rozen1, J Knaani, N Papo.   

Abstract

Guaiac tests for faecal occult blood are used for colorectal neoplasia screening. Specificity may be improved by using an immunochemical test for human blood. We evaluated and compared, within an endoscopic study, an immunochemical test for human stool albumin, BM-Test Colon Albumin, with the guaiac test, Hemoccult SENSA. Both tests were given to 527 screenees who had had a low-peroxidase diet before and during the tests. All had a colonoscopic (59%) or flexible sigmoidoscopic (41%) examination. Both tests were easy to perform and develop. They were of similar sensitivity (35-30%) for adenomas > or = 1.0 cm in diameter or cancers, but Colon Albumin had a higher specificity (90%) than Hemoccult (85%; P < 0.05). The latter, however, had a higher sensitivity for neoplasia of all sizes (25% vs 20%; NS) but lower specificity (85% vs 90%; P < 0.05). Colon Albumin was positive in 11.2%, while Hemoccult SENSA was positive in 16.7% and appears very sensitive to dietary peroxidases. Positivity was reduced to 7% by changing the methodology protocol. Overall, the guaiac test is more sensitive but less specific than the immunochemical test for colorectal neoplasia. However, the technical and diagnostic limitations of these tests must be appreciated, and because of their high positivity rate neither is suitable for mass screening. A more specific test for neoplasia is needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580783     DOI: 10.1097/00008469-199512000-00006

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  8 in total

Review 1.  Dietary interventions for fecal occult blood test screening: systematic review of the literature.

Authors:  Gerald Konrad
Journal:  Can Fam Physician       Date:  2010-03       Impact factor: 3.275

2.  Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test.

Authors:  P Rozen; J Knaani; Z Samuel
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia.

Authors:  P Rozen; J Knaani; Z Samuel
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

Review 4.  Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT).

Authors:  James E Allison; Callum G Fraser; Stephen P Halloran; Graeme P Young
Journal:  Gut Liver       Date:  2014-03-11       Impact factor: 4.519

5.  Correlating Quantitative Fecal Immunochemical Test Results with Neoplastic Findings on Colonoscopy in a Population-Based Colorectal Cancer Screening Program: A Prospective Study.

Authors:  Neal Shahidi; Laura Gentile; Lovedeep Gondara; Jeremy Hamm; Colleen E McGahan; Robert Enns; Jennifer Telford
Journal:  Can J Gastroenterol Hepatol       Date:  2016-12-26

6.  Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer.

Authors:  Takaya Shimura; Hiroyasu Iwasaki; Mika Kitagawa; Masahide Ebi; Tamaki Yamada; Tomonori Yamada; Takahito Katano; Hirotada Nisie; Yasuyuki Okamoto; Keiji Ozeki; Tsutomu Mizoshita; Hiromi Kataoka
Journal:  Transl Oncol       Date:  2019-01-03       Impact factor: 4.243

7.  Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012.

Authors:  Diana Redwood; Ellen Provost; Elvin Asay; Diana Roberts; Donald Haverkamp; David Perdue; Michael G Bruce; Frank Sacco; David Espey
Journal:  Prev Chronic Dis       Date:  2014-04-10       Impact factor: 2.830

Review 8.  Advances in Fecal Occult Blood Tests: the FIT revolution.

Authors:  Graeme P Young; Erin L Symonds; James E Allison; Stephen R Cole; Callum G Fraser; Stephen P Halloran; Ernst J Kuipers; Helen E Seaman
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.